4.6 on Google
4.6 on Google
sanctumHealthcare
Position paper · October 2026 · Download the PDF

Position paper · October 2026

The Review sees the system. It misses the whole person.

Sanctum Healthcare's response to the Independent review into prevalence and support for mental health conditions, ADHD and autism (final report, October 2026).

An open report on a green leather desk with a fountain pen and reading glasses

Summary

Our response in brief

We support the Review's direction. We think it has left out half of the picture.

The Independent Review led by Professor Peter Fonagy, with Professor Gillian Baird and Professor Sir Simon Wessely, is a serious and unusually candid piece of work. We support its central policy shift: help should not be locked behind a diagnosis.

But the Review explains rising demand almost entirely through social, educational and service-system factors. It largely leaves out the biological and behavioural factors that shape how ADHD and autism present, what they are mistaken for and what drives impairment. Those include sleep, iron and thyroid status, hormonal change across the lifespan, connective tissue and autonomic differences, emotional dysregulation, addictive behaviours and the physical health risks that shorten lives.

These omissions matter on the Review's own terms. It warns that misdiagnosis is a growing risk, that women and girls have been overlooked, that minority communities are under-served and that support should be matched to need. Each of those aims is weakened when the body is left out.

We also think the Review's headline on overdiagnosis goes further than its own data allow, particularly for ADHD. Section 2 sets out why.

Takeaway

What we are asking for

  1. Add a physiology and behaviour domain to the proposed needs framework (Annex A).
  2. Set a national minimum standard for ADHD and autism assessment that covers sleep, substances and behavioural addictions, hormonal history, emotional regulation and relevant physical health.
  3. Treat emotional dysregulation, sleep, substance use and physical health as treatment targets, with an annual physical health review for adults with ADHD.
  4. Build women's health and life stage into assessment and treatment pathways.
  5. Investigate the South Asian and Black diagnosis gaps, fund culturally valid assessment tools and correct the Review's error on autism recording in Black pupils.
  6. Use the next national surveys to measure hormonal stage, sleep, physical health and addictive behaviours.
  7. Extend the proposed model of care beyond age 25.
Two green velvet armchairs and a bronze lamp in a calm consulting room

Context

Why we are responding, and our interest

We work with people with ADHD and autism every day. We also have a stake in the Review's recommendations, and we say so.

Sanctum Healthcare is a CQC-registered independent service providing assessment and treatment for ADHD and autism in adults and children. Sanctum was originally set up to support people with ADHD and addiction, and we assess addictive behaviours as standard. Our clinical framework, the Brain Health Model, considers the brain and body together. Our not-for-profit arm, Sanctum Brain Health CIC, provides education and training.

We have read the full 599-page final report. Page references in this paper are to that report.

A long library table stacked with research reports and journals

Section 1 · Strengths

Much of the Review is right

The Review asks better questions than the public debate it responds to.

It keeps a careful distinction between population prevalence, recorded diagnosis, demand for assessment and need. It treats diagnosis as a clinical intervention with benefits and harms, rather than asking simply whether there is too much or too little of it. Its central recommendation, a move from a diagnosis-dependent system to a needs-led plus diagnosis system, is right: people should be supported before, during and after assessment.

Its account of ADHD medication in Chapter 7 is balanced. It sets out the evidence on reduced accidents, substance misuse, suicidal behaviour and criminality and finds no evidence of widespread harm from increased prescribing (pp. 148 to 150). Its section on parenting and early intervention is strong and honest about effects shrinking under independent evaluation. It is candid about what is not known: there is no adult ADHD prevalence survey and no child diagnostic survey since 2017 (p. 42).

On the independent sector, the Review is right that rapid growth has outpaced oversight. Tariffs vary around fourfold between integrated care boards, and only about 10 of roughly 120 ADHD providers submitted data (p. 329). We support consistent standards, regulation and outcome reporting for all providers, NHS and independent alike.

Takeaway

Our position

  1. We support the move to a needs-led plus diagnosis system.
  2. We support consistent standards, regulation and data reporting for every provider.
  3. We support better national data, including regular prevalence surveys.
A bronze balance scale with a stack of papers in one pan

Section 2 · The evidence

The headline on overdiagnosis outruns the data

The Review's Executive Summary is more confident than the chapters beneath it, especially for ADHD.

ADHD is compared with the wrong benchmark

The Executive Summary says recorded ADHD in young people is now "approaching and for some groups already exceeding" population estimates (p. 11). The example given is boys aged 12 to 17, at 5.1% (p. 131). But the benchmark is an estimate for boys and girls combined, aged 5 to 15: 3% in 2017, projected by the Review to about 3.8% now (p. 125).

Using the community sex ratio of about 2.3 to 1, an overall rate of 3.8% implies roughly 5.3% in boys and 2.3% in girls. The recorded rates for 12 to 17-year-olds are 5.1% and 2.7%. On the Review's own projection, recorded ADHD in adolescents matches the expected rate by sex. It does not exceed it. Chapter 12 says as much: recorded diagnoses "remain below community prevalence estimates in most age groups" (p. 267).

A rising line is what a capacity-limited system produces

The Review argues that if diagnosis were simply catching up with true prevalence, the rate of increase would slow (pp. 61, 130). That only holds when assessment capacity is not the constraint. With more than 560,000 open ADHD referrals (p. 129), the number of new diagnoses each year is set by throughput, not by how many undiagnosed people remain.

Autism is a different story, but its benchmark is weak

For autism the gap is real: cumulative recorded prevalence is 6.3% in boys aged 6 to 11 (p. 155), against a population anchor of about 1.0 to 1.2% from the 2017 national child survey. That survey's measures were not designed for autism case-finding, and recent US surveillance with active case-finding finds 27.7 per 1,000 White and 36.6 per 1,000 Black eight-year-olds (CDC 2025). Both readings, threshold drift and an anchor set too low, deserve testing. The Review treats ADHD and autism in parallel, which blurs where the signal is.

Screening questionnaires are used as if they measured disorder

The Review reports that 57% of 16 to 24-year-olds with a common mental disorder screen positive for ADHD and 61% for autistic traits (p. 139), and that autistic-trait positives in this group rose from 20% to 61% since 2007 (p. 198). A tripling of a developmental trait in 17 years is not plausible. Distress inflating screening scores is the likelier explanation, and the same survey shows complaints of poor concentration roughly doubling (p. 81).

The impairment claim rests on the wrong group

The Executive Summary states that "those now presenting are no less affected than those identified before" (p. 15). The evidence offered is about undiagnosed adults who screen positive in a household survey (p. 139), not people presenting to services. The chapter's own counter-evidence points the other way: weakening links between ADHD diagnosis and educational outcomes in South London and Norway, and a Danish registry study showing differences between diagnosed children and controls narrowing as diagnosis doubled (p. 140).

Several headline figures rest on weak sources

The Review sets out a sound framework for grading evidence (Table 3.1) but does not visibly apply it to its headline claims. The figures on independent-sector spending come from a think tank report (Centre for Health and the Public Interest) and on independent-sector share from the providers' own trade body. The NEET figure for ADHD comes from a preprint. Several primary care analyses are cited as unpublished personal communications. The key Norwegian finding on harms of diagnosis is from a manuscript under review (p. 70). The claim that misdiagnosis is more likely where assessment is "not face to face" (p. 14) is not supported anywhere in the body of the report.

Adults with ADHD are under-served

Among people who identify with ADHD, the average recalled age at which difficulties began rose from 9.8 years in 2014 to 21.7 years in 2024 (p. 135). The Review cites the Dunedin cohort on late-onset ADHD but not Sibley and colleagues' 2018 study. In that study about 95% of people who first screened positive for late-onset ADHD were excluded on careful, repeated assessment, most often because their symptoms occurred only alongside heavy substance use. Chapter 19 narrows medication to improving "attention, concentration or productivity" (pp. 399, 423), contradicting Chapter 7. And the proposed model of care covers ages 0 to 25 only (p. 408), although adults make up most ADHD demand.

Takeaway

Our reading

  1. The data support real concern about autism thresholds and about assessment quality everywhere.
  2. They do not show that ADHD is being overdiagnosed at scale, and the Review's own chapters say so.
  3. Better national data, as the Review recommends, is the way to settle the question.
A young woman sits on the edge of her bed at dawn

Section 3 · Gap one

A misdiagnosis argument without the body

The Review warns that misdiagnosis is rising. It never names the physical and behavioural conditions that most often mimic ADHD.

The Review is clear that attentional difficulties "may arise in anxiety, depression, trauma, sleep disturbance, substance misuse and many other conditions" (p. 146) and that comprehensive assessment is the safeguard. But it never says what comprehensive assessment must include, and its proposed standards for assessment (Recommendation 5) cover only co-occurring conditions, functioning, remote versus in-person assessment and assessor training.

Sleep and circadian rhythm

Sleep appears mainly as the route by which phones and social media harm young people (p. 241). The Review notes that insomnia, delayed sleep phase and restless legs are common in ADHD and autism (p. 202) but does not recommend sleep screening in assessment, and does not mention sleep apnoea, insomnia treatment or melatonin as a treatment.

Iron and thyroid

The words iron, ferritin, anaemia and thyroid do not appear in the body of the report. Iron deficiency is linked to ADHD, restless legs and poor sleep, and it is common in menstruating young women: the group whose distress and ADHD diagnoses have risen fastest.

Hormonal change

Across 599 pages, menopause is mentioned once (p. 103) and hormonal change once (p. 180). There is nothing on the menstrual cycle, premenstrual dysphoric disorder, the postpartum period, perimenopause, contraception or HRT. A woman in her mid-forties presenting for the first time with new attentional problems, low mood and poor sleep is exactly where perimenopause is both a contributor and a source of diagnostic confusion. The Review has nothing to say about her.

Connective tissue, autonomic and immune differences

The Review records the Ehlers-Danlos association (p. 202) and lists POTS and hypermobile Ehlers-Danlos among conditions "often grouped under the umbrella of medically unexplained symptoms" without questioning that label, although both have established diagnostic criteria. It notes their overlapping fatigue, dizziness and poor concentration, then does not follow the point through to assessment. Inflammation, histamine and mast cell activation are not discussed. Evidence on these is still emerging and the right ask is research, not clinical mandates.

Substances, caffeine and screens

Intoxication and withdrawal from stimulants, cannabis, nicotine and caffeine can mimic or mask inattention, as can heavy phone use. The Review notes that ADHD is often missed in substance misuse services (p. 299) but sets no expectation that ADHD assessment covers substance use. Caffeine is not mentioned; nicotine appears only as a public health analogy.

Takeaway

What this means

  1. Before attention difficulties are attributed to ADHD, assessment should consider the common physical and behavioural mimics.
  2. The Review asks for comprehensive assessment but never defines it. A national minimum standard should.
A mother helps her teenage daughter with homework at the kitchen table

Section 4 · Gap two

The groups the Review prioritises are the least described

Women, girls and minority communities are at the centre of the Review's data. Their specific needs are largely missing from its analysis.

Women and girls

The Review's own data keep pointing at women. Common mental disorder among women aged 16 to 24 rose from 20.5% to 36.1% (p. 84). Recorded ADHD rose more than tenfold in females between 2017 and 2025, against threefold in males (p. 131). Recorded autism incidence in females now exceeds that in males from adolescence onwards (p. 169). The Review explains this through awareness, masking, social media and educational pressure. It does not consider hormones, pregnancy, life stage or the specific risks women with ADHD and autism face.

Each has practical consequences. Late diagnosis means years of treatment for the wrong problem. Early pregnancy raises questions about ADHD medication in pregnancy and the postpartum period that the Review does not address. The overlap with borderline personality disorder is a well-known source of misdiagnosis in women, yet how often autistic women are misdiagnosed with it has never been measured (May 2021). The Review notes that the link between eating disorders and ADHD has strengthened (p. 381) but does not consider what that means for prescribing an appetite-suppressing medication.

Minority communities

The Review reports recorded prevalence by ethnicity from primary care records. For ADHD: Mixed 2.0%, White 1.7%, Black 0.7% and South Asian 0.4% (p. 132). It concludes it cannot say why. Several things it could have said are missing.

The South Asian gap is very large. In Bradford, White British children were diagnosed with ADHD 5.3 times (boys) and 5.8 times (girls) as often as South Asian children (Warburton 2026). International evidence points to under-diagnosis rather than lower prevalence. Assessment tools behave differently across groups, and there are no UK norms by ethnicity for the main ADHD rating scales. Language matters too: pupils who speak another language at home are less likely to have autism recorded.

The Review also contains a factual error. It says autism-related special educational needs were "recorded less often" for Black pupils, citing 2.11% (p. 311). Its source shows Black pupils had the highest recorded autism prevalence of any group (Roman-Urrestarazu 2021).

Takeaway

What this means

  1. Women need assessment and treatment that take account of hormones, pregnancy and life stage.
  2. Minority communities need culturally valid tools, adapted pathways and research into why the gaps exist.
  3. Without these, the Review's commitment to under-served groups stays a statement of intent.
A man pauses after a run on a Manchester canal towpath at dusk

Section 5 · Gap three

Need is shaped by emotion, behaviour and physical health

The things that often decide how well someone with ADHD lives are missing from the Review's needs framework and treatment plan.

Emotional dysregulation

The Review records that emotional dysregulation predicts later impairment beyond ADHD symptoms (p. 141), and its lived experience partners describe it as the most disabling part of their ADHD and the part medication helped most (p. 149). Yet it never becomes part of how ADHD is assessed or treated. The Review lists portrayals of "mood instability" as characteristic of ADHD among the inaccuracies of social media content (p. 143).

Rejection sensitive dysphoria is not mentioned. It has no validated measure or prevalence data and is not a diagnostic entity. But it is one of the most widely used ADHD concepts in exactly the spaces the Review studies, and clinicians need guidance on it.

Addictive behaviours

The word addiction appears once in the body of the report, in a list of under-delivered therapies (p. 420). Gambling appears once, as a social determinant (p. 434). Gaming disorder, an ICD-11 diagnosis, is not mentioned. Provision for young people with substance misuse problems shrank while other mental health provision grew (p. 337). Impulsivity, reward sensitivity and using behaviour to manage emotion are the processes the Review itself calls transdiagnostic (p. 192), yet it does not connect them to addictive behaviour in ADHD.

Physical health and life expectancy

In the UK, life expectancy is 6.8 years shorter for men and 8.6 years shorter for women with diagnosed ADHD (O'Nions 2025). The Review mentions reduced life expectancy (p. 69) and asks for "proactive physical health review" (p. 400), but sets no standard. People with severe mental illness are offered an annual physical health check. Adults with ADHD are not.

Medication's effects on these outcomes belong in the treatment discussion. Chapter 7 covers them; Chapter 19 drops them.

Lifestyle

Physical activity is described as "one of the few individual-level protective factors supported by prospective evidence" (p. 347) but only as population prevention. Diet gets one sentence (p. 373). Nothing is said about exercise or nutrition as part of ADHD care, or about the myths a public information campaign (Recommendation 9) could correct.

Takeaway

What this means

  1. Emotional regulation, addictive behaviours, sleep and physical health belong in the needs framework and the treatment plan.
  2. Adults with ADHD should have a proactive physical health review, as people with severe mental illness do.
A hand annotating architectural plans on a drafting table

Section 6 · Recommendations

Seven changes that would complete the Review

None of these changes alters the Review's direction. Each is mapped to a recommendation the Review already makes.

  1. Needs framework (Recommendation 2, Annex A). Add a seventh dimension, physiology and behaviour, covering sleep, physical health, hormonal stage, substances and behavioural addictions, emotional regulation and eating.
  2. Assessment standard (Recommendation 5). Set a national minimum content for ADHD and autism assessment: structured screening for sleep disorders; substances including nicotine, caffeine and cannabis; behavioural addictions including gambling, gaming and spending; menstrual, perinatal and menopausal history; emotional dysregulation; eating behaviour; and proportionate physical health checks, including ferritin and thyroid function where clinically indicated.
  3. Treatment and follow-up (Recommendation 4). Treatment plans should address emotional dysregulation, sleep, substance use and lifestyle. Adults with ADHD should be offered an annual physical health review. Chapter 19 should restore Chapter 7's account of what medication achieves.
  4. Women's health (Recommendations 3 and 4). Build menstrual, perinatal and perimenopausal presentations into pathways, with national guidance on ADHD medication in pregnancy and after birth and joint working with women's health hubs.
  5. Equity (Recommendations 3 and 8). Investigate the South Asian and Black diagnosis gaps, commission UK normative data for ADHD and autism tools across ethnic groups, fund culturally adapted pathways and correct the error on p. 311.
  6. Data, research and public information (Recommendations 8 and 9). Include hormonal stage, sleep, physical health and addictive behaviour measures in the next national surveys. Prioritise research on hormonal effects on ADHD and stimulant response, iron, hypermobility and dysautonomia, mast cell activation and whether rejection sensitive dysphoria is a valid construct. Use the public information campaign to address sleep, substances and nutrition myths.
  7. Life course (Recommendations 3 and 10). Extend the 0 to 25 model of care and the Annex A framework to adults, who make up most ADHD demand.

Takeaway

The principle

  • Diagnosis alone is an incomplete guide to need. So is a needs framework that leaves out the body.
Clinicians and commissioners in discussion around a meeting table

Section 7 · Working together

Brain and body, assessed together

We would welcome the chance to help test what we propose.

The changes we propose are practical. Most can be built into assessment templates and care plans that services already use. The weaker parts of the evidence, on hormones, iron, dysautonomia and rejection sensitivity, call for careful research rather than new mandates, and we have labelled them that way throughout.

We would welcome working with the Department of Health and Social Care, NHS England, integrated care boards and the Review team to test a physiology and behaviour domain within the proposed needs framework, and to share what we learn.

Stacked research papers with bronze page markers

Appendix

The evidence, gap by gap

How the Review handles each factor, and the best verified figure for ADHD and autism.

Strength: Strong = large registry or meta-analysis with consistent findings. Moderate = meta-analysis with heterogeneity, or a single large cohort. Emerging = small or single studies. Weak = observational or inconsistent. Figures checked against PubMed or official statistics in October 2026. Most figures are odds or risk ratios because that is how the research reports them; we have not converted them into percentages.

Sex, gender and hormones

FactorIn the ReviewADHDAutismStrengthSource
True sex ratioRecorded trends onlyCommunity children 2.3:1; adults 1.6:1; clinic samples 3:1 to 16:1Pooled 4.2:1; about 3:1 in high-quality screened studiesStrongWillcutt 2012; Young 2020; Loomes 2017
Later diagnosis in womenGeneral onlyAbout 4 years later (23.5 vs 19.6)Later, no reliable pooled figureModerateSkoglund 2023
PMDD and postpartum depressionAbsentPMDD symptoms 45.5%; postpartum depression 57.6% of mothersNo dataEmergingDorani 2021
Menstrual cycle and oestrogenAbsentSymptoms and stimulant effects vary with oestradiol; no trial in ADHDNo dataEmergingRoberts 2017; Wynchank 2025
Teenage and unplanned pregnancyAbsentTeenage birth 15.3% vs 2.8%; unplanned pregnancy 39 to 48% vs 10.6%No dataStrongSkoglund 2019; Owens 2017
Sexual and partner violenceNot addressedSexual violence OR 1.84; partner violence OR 1.7888.4% of autistic women (self-selected survey)ModerateArrondo 2023; Cazalis 2022
Borderline personality disorderCo-occurrence onlyaOR 19.4; ADHD in 16 to 38% of clinical BPDOverlap 3 to 4%; misdiagnosis not measuredModerateKuja-Halkola 2018; Weiner 2019; May 2021
Eating disordersPartlyBulimia OR 5.71; binge eating OR 4.13; anorexia OR 4.2829% of people with anorexia above ADOS cut-offModerateNazar 2016; Inal-Kaleli 2024
Gender diversityBrief (p. 111)Similar to autism (figure not verified)3.0 to 6.4 times as likelyStrongWarrier 2020
PCOSAbsentMaternal PCOS: offspring OR 1.42Women with PCOS aOR 1.55; maternal PCOS offspring OR 1.44ModerateCesta 2016; Cao 2026

Ethnicity

FactorIn the ReviewADHDAutismStrengthSource
South Asian gapRecorded rates onlyBradford: White British diagnosed 5.3 (boys) and 5.8 (girls) times as often; incidence 1.8 vs 0.3 per 1,000 person-yearsAsian pupils 0.83 vs WhiteModerateWarburton 2026; Pettinger 2025; Roman-Urrestarazu 2021
Under-diagnosis vs prevalenceNot discussedBlack children 69% lower adjusted odds of diagnosis; similar pooled prevalence–ModerateMorgan 2013; Cénat 2022
Autism in English schoolsMisreported (p. 311)–Chinese 1.38, Black 1.26, Roma or Irish Traveller 0.42; other home language 0.64StrongRoman-Urrestarazu 2021
Autism with intellectual disabilityAbsent–Black 52.8% vs White 32.7%StrongCDC 2025
Tool biasAbsentTeacher ratings function differently by race; no UK ethnic norms8 ADOS items differ, little total effect; AQ higher in Indian samplesModerateDuPaul 2020; Kalb 2022; Freeth 2013
ExclusionSEND onlySuspensions per 100: Gypsy or Roma 33.7; Black Caribbean 13.6; all 9.3; SEN support 28.9 vs 6.8–StrongDfE

Brain and body

FactorIn the ReviewADHDAutismStrengthSource
Sleep and circadianPartlyDelayed melatonin onset (31 of 40); restless legs 11 to 43% children, 20 to 33% adults; sleep-disordered breathing g 0.57Sleep-wake disorder 13%; problems in mostModerateVan Veen 2010; Migueis 2023; Sedky 2014; Lai 2019
IronAbsentIron deficiency OR 1.64No differenceModerateTseng 2018; Wang 2017
ThyroidAbsentMaternal hypothyroidism OR 1.14OR 1.41WeakGe 2020
Obesity and metabolicListedAdult obesity 28.2% vs 16.4%; type 2 diabetes OR 2.29Child obesity 17%, RR 1.58StrongCortese 2016; Garcia-Argibay 2023; Sammels 2022
Hypermobility and EDSOne lineIn EDS RR 5.6; hypermobility aOR 4.7In EDS RR 7.4; hypermobility aOR 3.1ModerateCederlöf 2016; Glans 2021; Glans 2022
DysautonomiaNamed onceNo prevalence dataLower heart rate variability g −0.52EmergingCheng 2020
Allergy and autoimmuneListedAsthma OR 1.53; eczema OR 1.32; autoimmune IRR 1.24Food allergy 11.3% vs 4.3%StrongCortese 2018; Schans 2017; Nielsen 2017; Xu 2018
Inflammation and mast cellsAbsentIL-6 higher (fragile)Maternal infection OR 1.30; mast cell data emergingEmergingMisiak 2022; Jiang 2016
EpilepsyListedIn epilepsy OR 3.4712.1%StrongBrikell 2018; Lukmanji 2019
GutListed–GI symptoms OR 4.42ModerateMcElhanon 2014
MigraineAbsentOR 1.32–ModerateSalem 2018
AlexithymiaOne wordAbout 22% (small study)49.9% vs 4.9%Strong (autism)Kinnaird 2019; Edel 2010
Physical multimorbidityGeneralRaised risk for 34 of 35 conditions–StrongDu Rietz 2021
Life expectancy (UK)No figures6.8 years shorter (men), 8.6 (women)–StrongO'Nions 2025

Emotion and mood

FactorIn the ReviewADHDAutismStrengthSource
Emotional dysregulationNot in definition25 to 45% children; 30 to 70% adults; g 1.17About 4 times norm (youth)ModerateShaw 2014; Beheshti 2020; Conner 2021
Rejection sensitive dysphoriaAbsentNo validated measure or prevalence–WeakGinapp 2023
BipolarNot linked7.95% of adults with ADHD; 17.1% of people with bipolar have ADHD–StrongSchiweck 2021
Anxiety and depressionScreens onlyAnxiety OR 5.0; depression OR 4.5–StrongHartman 2023
SuicideGeneralAttempts OR 2.37; death OR 6.69; stimulants RR 0.75Death RR 2.85; lifetime attempts 15.3%StrongSeptier 2019; Liu 2020; Santomauro 2024; Huntjens 2023

Addictive behaviours and lifestyle

FactorIn the ReviewADHDAutismStrengthSource
Substance use disorderCo-occurrence23.1% of people with SUD have ADHD; adults OR 4.6Risk doubled without ADHDStrongvan Emmerik-van Oortmerssen 2012; Hartman 2023; Butwicka 2017
Nicotine and vapingAbsentDependence OR 2.82; vaping aOR 1.60–StrongLee 2011; McCabe 2025
Cannabis and alcoholGeneralCannabis OR 2.78; alcohol use disorder OR 1.74–ModerateLee 2011
CaffeineAbsentEvening caffeine 2.5 times as likely (adolescents)–WeakCusick 2020
GamblingOne wordr 0.17–ModerateTheule 2019
Internet, gaming, social mediaPopulation onlyInternet addiction OR 2.85; gaming r 0.30; social media r 0.36Problematic internet use r 0.26ModerateHo 2014; Koncz 2023; Ding 2025; Muris 2025
Spending and debtImpairment onlyDefaults rise in middle age–ModerateBeauchaine 2020
Accidents and sexual riskGeneralInjury OR 1.53; crashes lower on medication; STI HR 3.36–StrongRuiz-Goikoetxea 2018; Chang 2017; Chen 2018
ExercisePrevention onlyCore symptoms SMD 0.50–EmergingZhu 2026
DietOne sentenceOmega-3 g 0.38; food colours small; sugar no effect–ModerateChang 2018; Nigg 2012; Wolraich 1995

References

Sources

Titles are abbreviated. Page numbers in the text refer to the Review's final report. Photography is illustrative, generated with Midjourney, and does not show patients or real people.

  1. Fonagy, Baird and Wessely 2026. Fonagy P, Baird G, Wessely S. Independent review into prevalence and support for mental health conditions, ADHD and autism: final report. October 2026.
  2. Arrondo 2023. Arrondo et al. ADHD and interpersonal and sexual violence. Psychological Medicine. doi.org/10.1017/S0033291723001976
  3. Beauchaine 2020. Beauchaine et al. ADHD, financial distress and suicide in adulthood. Science Advances. doi.org/10.1126/sciadv.aba1551
  4. Beheshti 2020. Beheshti et al. Emotion dysregulation in adults with ADHD: a meta-analysis. BMC Psychiatry. doi.org/10.1186/s12888-020-2442-7
  5. Brikell 2018. Brikell et al. The contribution of common genetic risk variants for ADHD to epilepsy. Biological Psychiatry. doi.org/10.1016/j.biopsych.2017.08.006
  6. Butwicka 2017. Butwicka et al. Risks of substance use in autism spectrum disorder. J Autism Dev Disord. doi.org/10.1007/s10803-016-2914-2
  7. Cao 2026. Cao et al. Maternal PCOS and offspring neurodevelopmental disorders: meta-analysis. BMC Psychiatry. doi.org/10.1186/s12888-026-08047-4
  8. Cazalis 2022. Cazalis et al. Evidence that nine autistic women out of ten have been victims of sexual violence. Front Behav Neurosci. doi.org/10.3389/fnbeh.2022.852203
  9. CDC 2025. Shaw et al. Prevalence of autism spectrum disorder among children aged 8 years. MMWR Surveill Summ 74(2). www.cdc.gov/mmwr/volumes/74/ss/ss7402a1.htm
  10. Cederlöf 2016. Cederlöf et al. Ehlers-Danlos syndrome and neurodevelopmental disorders. BMC Psychiatry. doi.org/10.1186/s12888-016-0922-6
  11. Cesta 2016. Cesta et al. Polycystic ovary syndrome and psychiatric disorders. Psychoneuroendocrinology. doi.org/10.1016/j.psyneuen.2016.08.005
  12. Chang 2017. Chang et al. ADHD medication and motor vehicle crashes. JAMA Psychiatry. doi.org/10.1001/jamapsychiatry.2017.0659
  13. Chang 2018. Chang et al. Omega-3 fatty acids in youth with ADHD: meta-analysis. Neuropsychopharmacology. doi.org/10.1038/npp.2017.160
  14. Chen 2018. Chen et al. Sexually transmitted infection in ADHD and the effect of medication. J Am Acad Child Adolesc Psychiatry. doi.org/10.1016/j.jaac.2017.09.438
  15. Cheng 2020. Cheng et al. Heart rate variability in autism: meta-analysis. Neurosci Biobehav Rev. doi.org/10.1016/j.neubiorev.2020.08.007
  16. Conner 2021. Conner et al. Emotion dysregulation in autistic youth. Autism Research. doi.org/10.1002/aur.2450
  17. Cortese 2016. Cortese et al. ADHD and obesity: meta-analysis. Am J Psychiatry. doi.org/10.1176/appi.ajp.2015.15020266
  18. Cortese 2018. Cortese et al. ADHD and asthma: meta-analysis and register study. Lancet Psychiatry. doi.org/10.1016/S2215-0366(18)30224-4
  19. Cusick 2020. Cusick et al. Caffeine use and sleep in adolescents with and without ADHD. J Pediatr Psychol. doi.org/10.1093/jpepsy/jsaa033
  20. Cénat 2022. Cénat et al. Prevalence of ADHD among Black, White, Latino and Asian youth: meta-analysis. J Clin Child Adolesc Psychol. doi.org/10.1080/15374416.2022.2051524
  21. DfE. Department for Education. Pupil exclusions by ethnicity; suspensions and permanent exclusions in England. www.ethnicity-facts-figures.service.gov.uk/education-skills-and-training/absence-and-exclusions/pupil-exclusions/latest/
  22. Ding 2025. Ding et al. Problematic social media use and ADHD symptoms: meta-analysis. J Psychiatr Res. doi.org/10.1016/j.jpsychires.2025.07.009
  23. Dorani 2021. Dorani et al. Prevalence of hormone-related mood disorder symptoms in women with ADHD. J Psychiatr Res. doi.org/10.1016/j.jpsychires.2020.12.005
  24. Du Rietz 2021. Du Rietz et al. Physical conditions in adults with ADHD. Lancet Psychiatry. doi.org/10.1016/S2215-0366(21)00171-1
  25. DuPaul 2020. DuPaul et al. Invariance of ADHD symptom ratings by race. J Abnorm Child Psychol. doi.org/10.1007/s10802-020-00618-7
  26. Edel 2010. Edel et al. Alexithymia, emotion processing and social anxiety in adults with ADHD. Eur J Med Res. doi.org/10.1186/2047-783x-15-9-403
  27. Freeth 2013. Freeth et al. The Autism-Spectrum Quotient across cultures. J Autism Dev Disord. doi.org/10.1007/s10803-013-1808-9
  28. Garcia-Argibay 2023. Garcia-Argibay et al. ADHD and type 2 diabetes: meta-analysis and register study. Neurosci Biobehav Rev. doi.org/10.1016/j.neubiorev.2023.105076
  29. Ge 2020. Ge et al. Maternal thyroid dysfunction and offspring neurodevelopmental disorders: meta-analysis. J Clin Endocrinol Metab. doi.org/10.1210/clinem/dgaa555
  30. Ginapp 2023. Ginapp et al. The lived experiences of adults with ADHD. PLoS One. doi.org/10.1371/journal.pone.0292721
  31. Glans 2021. Glans et al. Generalised joint hypermobility in adults with ADHD. J Psychiatr Res. doi.org/10.1016/j.jpsychires.2021.07.006
  32. Glans 2022. Glans et al. Joint hypermobility in autistic adults. Front Psychiatry. doi.org/10.3389/fpsyt.2021.803334
  33. Hartman 2023. Hartman et al. Psychiatric comorbidity in adult ADHD: meta-analysis of large datasets. Neurosci Biobehav Rev. doi.org/10.1016/j.neubiorev.2023.105209
  34. Ho 2014. Ho et al. Internet addiction and psychiatric comorbidity: meta-analysis. BMC Psychiatry. doi.org/10.1186/1471-244X-14-183
  35. Huntjens 2023. Huntjens et al. Suicidal ideation and behaviour in autism: meta-analysis. Crisis. doi.org/10.1027/0227-5910/a000922
  36. Inal-Kaleli 2024. Inal-Kaleli et al. Autism in anorexia nervosa: meta-analysis. Int J Eat Disord. doi.org/10.1002/eat.24307
  37. Jiang 2016. Jiang et al. Maternal infection during pregnancy and autism: meta-analysis. Brain Behav Immun. doi.org/10.1016/j.bbi.2016.06.005
  38. Justice and de Wit 1999. Justice, de Wit H. Acute effects of d-amphetamine during the menstrual cycle. Psychopharmacology. doi.org/10.1007/s002130051033
  39. Kalb 2022. Kalb et al. ADOS-2 measurement invariance by race and ethnicity. JAMA Netw Open. doi.org/10.1001/jamanetworkopen.2022.9498
  40. Kinnaird 2019. Kinnaird et al. Alexithymia in autism: meta-analysis. Eur Psychiatry. doi.org/10.1016/j.eurpsy.2018.09.004
  41. Koncz 2023. Koncz et al. ADHD and gaming disorder: meta-analysis. Clin Psychol Rev. doi.org/10.1016/j.cpr.2023.102343
  42. Kuja-Halkola 2018. Kuja-Halkola et al. Codevelopment of ADHD and borderline personality disorder. Mol Psychiatry. doi.org/10.1038/s41380-018-0248-5
  43. Lai 2019. Lai et al. Prevalence of co-occurring mental health diagnoses in autism: meta-analysis. Lancet Psychiatry. doi.org/10.1016/S2215-0366(19)30289-5
  44. Lee 2011. Lee et al. Childhood ADHD and later substance use: meta-analysis. Clin Psychol Rev. doi.org/10.1016/j.cpr.2011.01.006
  45. Liu 2020. Liu et al. ADHD medication and suicidal behaviour: meta-analysis. Pharmacoepidemiol Drug Saf. doi.org/10.1002/pds.5110
  46. Loomes 2017. Loomes et al. The male-to-female ratio in autism: meta-analysis. J Am Acad Child Adolesc Psychiatry. doi.org/10.1016/j.jaac.2017.03.013
  47. Lukmanji 2019. Lukmanji et al. Epilepsy in autism: systematic review. Epilepsy Behav. doi.org/10.1016/j.yebeh.2019.07.037
  48. May 2021. May et al. Autism and borderline personality disorder: meta-analysis. Autism Research. doi.org/10.1002/aur.2619
  49. McCabe 2025. McCabe et al. ADHD symptoms and e-cigarette initiation. JAMA Netw Open. doi.org/10.1001/jamanetworkopen.2024.58834
  50. McElhanon 2014. McElhanon et al. Gastrointestinal symptoms in autism: meta-analysis. Pediatrics. doi.org/10.1542/peds.2013-3995
  51. Migueis 2023. Migueis et al. Restless legs syndrome and ADHD: systematic review. Sleep Med Rev. doi.org/10.1016/j.smrv.2023.101770
  52. Misiak 2022. Misiak et al. Inflammatory markers in ADHD: meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. doi.org/10.1016/j.pnpbp.2022.110581
  53. Morgan 2013. Morgan et al. Racial and ethnic disparities in ADHD diagnosis. Pediatrics. doi.org/10.1542/peds.2012-2390
  54. Muris 2025. Muris et al. Autism and problematic internet use: meta-analysis. Clin Child Fam Psychol Rev. doi.org/10.1007/s10567-025-00524-8
  55. Nazar 2016. Nazar et al. ADHD and eating disorders: meta-analysis. Int J Eat Disord. doi.org/10.1002/eat.22643
  56. Nielsen 2017. Nielsen et al. ADHD and autoimmune diseases. J Am Acad Child Adolesc Psychiatry. doi.org/10.1016/j.jaac.2016.12.010
  57. Nigg 2012. Nigg et al. Restriction diets and artificial food colours in ADHD: meta-analysis. J Am Acad Child Adolesc Psychiatry. doi.org/10.1016/j.jaac.2011.10.015
  58. O'Nions 2025. O'Nions et al. Life expectancy and years of life lost in UK adults with diagnosed ADHD. Br J Psychiatry. doi.org/10.1192/bjp.2024.199
  59. Owens 2017. Owens, Hinshaw SP. Unplanned pregnancy in women with childhood ADHD. J Consult Clin Psychol. doi.org/10.1037/ccp0000217
  60. Pettinger 2025. Pettinger et al. Neurodevelopmental diagnoses in Born in Bradford. Dev Med Child Neurol. doi.org/10.1111/dmcn.16396
  61. Roberts 2017. Roberts et al. Ovarian hormones and ADHD symptoms across the cycle. Psychoneuroendocrinology. doi.org/10.1016/j.psyneuen.2017.11.015
  62. Roman-Urrestarazu 2021. Roman-Urrestarazu et al. Race, ethnicity, social disadvantage and autism in English schools. JAMA Pediatrics. doi.org/10.1001/jamapediatrics.2021.0054
  63. Ruiz-Goikoetxea 2018. Ruiz-Goikoetxea et al. ADHD, injuries and the effect of medication: meta-analysis. Neurosci Biobehav Rev. doi.org/10.1016/j.neubiorev.2017.11.007
  64. Salem 2018. Salem et al. ADHD and migraine: meta-analysis. Eur Child Adolesc Psychiatry. doi.org/10.1007/s00787-017-1045-4
  65. Sammels 2022. Sammels et al. Autism and obesity in children: meta-analysis. Obesity Facts. doi.org/10.1159/000523943
  66. Santomauro 2024. Santomauro et al. Suicide mortality in autism: meta-analysis. Psychiatry Res. doi.org/10.1016/j.psychres.2024.116150
  67. Schans 2017. Schans et al. ADHD and atopic diseases: meta-analysis. Neurosci Biobehav Rev. doi.org/10.1016/j.neubiorev.2017.01.011
  68. Schiweck 2021. Schiweck et al. Comorbidity of ADHD and bipolar disorder: meta-analysis. Neurosci Biobehav Rev. doi.org/10.1016/j.neubiorev.2021.01.017
  69. Sedky 2014. Sedky et al. ADHD and sleep-disordered breathing: meta-analysis. Sleep Med Rev. doi.org/10.1016/j.smrv.2013.12.003
  70. Septier 2019. Septier et al. ADHD and suicidal behaviour: meta-analysis. Neurosci Biobehav Rev. doi.org/10.1016/j.neubiorev.2019.05.022
  71. Shaw 2014. Shaw et al. Emotion dysregulation in ADHD. Am J Psychiatry. doi.org/10.1176/appi.ajp.2013.13070966
  72. Sibley 2018. Sibley et al. Late-onset ADHD reconsidered with comprehensive repeated assessments between ages 10 and 25. Am J Psychiatry. doi.org/10.1176/appi.ajp.2017.17030298
  73. Skoglund 2019. Skoglund et al. ADHD and teenage motherhood. JAMA Netw Open. doi.org/10.1001/jamanetworkopen.2019.12463
  74. Skoglund 2023. Skoglund et al. Sex differences in age at ADHD diagnosis. J Child Psychol Psychiatry. doi.org/10.1111/jcpp.13920
  75. Theule 2019. Theule et al. ADHD and gambling: meta-analysis. J Atten Disord. doi.org/10.1177/1087054715626512
  76. Tseng 2018. Tseng et al. Iron status in ADHD: meta-analysis. Scientific Reports. doi.org/10.1038/s41598-017-19096-x
  77. van Emmerik-van Oortmerssen 2012. van Emmerik-van Oortmerssen K et al. ADHD in substance use disorder populations: meta-analysis. Drug Alcohol Depend. doi.org/10.1016/j.drugalcdep.2011.12.007
  78. Van Veen 2010. Van Veen et al. Delayed circadian rhythm in adults with ADHD and chronic sleep-onset insomnia. Biol Psychiatry. doi.org/10.1016/j.biopsych.2009.12.032
  79. Wang 2017. Wang et al. Iron status in ADHD: meta-analysis. PLoS One. doi.org/10.1371/journal.pone.0169145
  80. Warburton 2026. Warburton et al. ADHD diagnosis by ethnicity in linked Bradford school and primary care records. Arch Dis Child. doi.org/10.1136/archdischild-2025-329285
  81. Warrier 2020. Warrier et al. Elevated rates of autism in transgender and gender-diverse individuals. Nature Communications. doi.org/10.1038/s41467-020-17794-1
  82. Weiner 2019. Weiner et al. ADHD and borderline personality disorder in adults. Neuropsychiatr Dis Treat. doi.org/10.2147/NDT.S192871
  83. Willcutt 2012. Willcutt EG. The prevalence of DSM-IV ADHD: meta-analytic review. Neurotherapeutics. doi.org/10.1007/s13311-012-0135-8
  84. Wolraich 1995. Wolraich et al. The effect of sugar on behaviour or cognition in children: meta-analysis. JAMA. doi.org/10.1001/jama.1995.03530200053037
  85. Wynchank 2025. Wynchank et al. Female sex hormones and ADHD: narrative review. J Clin Med. doi.org/10.3390/jcm15010121
  86. Xu 2018. Xu et al. Food, respiratory and skin allergies in children with autism. JAMA Netw Open. doi.org/10.1001/jamanetworkopen.2018.0279
  87. Young 2020. Young et al. Females with ADHD: expert consensus statement. BMC Psychiatry. doi.org/10.1186/s12888-020-02707-9
  88. Zhu 2026. Zhu et al. Exercise interventions for ADHD: umbrella review. Psychiatry Res. doi.org/10.1016/j.psychres.2026.117267

Sanctum Healthcare · Manchester | London | Cheshire

Sanctum Healthcare Logo 2024
Google Reviews for Sanctum Healthcare
Sanctum Healthcare Logo 2024
Call 0161 768 7634
Regulation and certification

Our Wilmslow clinic, 3 The Beeches, is registered with and inspected by the Care Quality Commission. Our website is certified by LegitScript.

Read the full CQC report
Care Quality Commission